# EDGAR Filing Document

**Accession Number:** 0001335105
**File Stem:** 0001641172-25-016613
**Filing Date:** 2025-6
**Character Count:** 2217
**Document Hash:** cd473d4bb785d1a5d8eecf16a975894e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-016613.hdr.sgml**: 20250812

**ACCESSION NUMBER**: 0001641172-25-016613

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250626

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001335105
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 202903526
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 248 ROUTE 25A
- **STREET 2:** NO. 2
- **CITY:** EAST SETAUKET
- **STATE:** NY
- **ZIP:** 11733
- **BUSINESS PHONE:** 310 203 2902

**MAIL ADDRESS:**
- **STREET 1:** 248 ROUTE 25A
- **STREET 2:** NO. 2
- **CITY:** EAST SETAUKET
- **STATE:** NY
- **ZIP:** 11733

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SRKP 7 INC
- **DATE OF NAME CHANGE:** 20050803

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

680 East Colorado Boulevard, Suite 180

Pasadena, California 91101

June 26, 2025

<u>VIA EDGAR</u>

Securities and Exchange Commission<br> Division of Corporation Finance

100 F. Street, N.E.

Washington, D.C. 20549

Re: Lixte Biotechnology Holdings, Inc. <br> Registration Statement on Form S-1 <br> <u>File No. 333-288120</u>

Ladies and Gentlemen:

Reference is made to our letter, filed as correspondence via EDGAR on June 24, 2025, in which we requested the acceleration of the effective date of the above-referenced Registration Statement for Thursday June 26, 2025 at 5:00 p.m. Eastern Time in accordance with Rule 461 under the Securities Act of 1933, as amended, We are no longer requesting that the Registration Statement be declared effective at this time and we are hereby formally withdrawing our request for acceleration of the effective date. Please call our counsel, David Ficksman of TroyGould PC at 818 469 4200 if you have any questions.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| LIXTE BIOTECHNOLOGY HOLDINGS, INC. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. |
| By: | */s/ Geordan Pursglove* |
|  | Geordan Pursglove |
|  | Chief Executive Officer |

---